Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Wealth creation)

Innovation 'Elevator Pitch':
NHS bed availability is very low which results in patients being placed in other Trusts, sometimes miles away from their home. Latebeds is an online service for sharing bed availability across the NHS and private care providers.
Overview of Innovation:
The original problem brought to Answer Digital Health by Sussex Partnership NHS Foundation Trust and shared by several, if not all, NHS Trusts is that internal bed availability is very low which results in patients being placed in other Trusts, sometimes miles away from their home making the situation of care difficult for the patient and their families. As well as disruption for patients, it also causes high administration and on-going care costs with external Trusts and private organisations.

The opportunity here is the introduction of the concept system Latebeds. Latebeds is an online service for sharing bed availability within Trusts across the NHS and private care providers.  

The system allows Bed Managers to search for available beds within the care and distance constraints that the patient requires. Following a successful search the Bed Manager can make a request to reserve the bed for their patient.

The idea is to use a simple ‘App’ (a cloud hosted service that could later be integrated into existing systems) across multiple device platforms that lists beds available internally and those available for booking externally. Criteria would allow for different bed types for patients of age, sex or 'tier'. Using Google maps it could have a ‘find a bed’ function that would filter by location (postcode), and the different criteria set.

It could also have the info on beds from private providers if they wished to join in (or we could put it in). Plus we could look later at more functionality (on a ‘Roadmap’) or even integrating it with different systems (eg Paris, RiO etc.).

Sussex Partnership Trust came up with the idea after a competition run by NHS England ‘Code4Health’ team (https://code-4-health.org/). A small company in Leeds (called www.AnswerDigital.com) have built a demo App to prove the concept and we are hoping to generate more interest in the idea to form a Community of Interest regionally and nationally.
 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
  1. Patients being placed nearer to home
  2. Direct Cost savings for the NHS from reduced number of Out of Area placements
  3. Directo Cost savings for the NHS from increased information about the relative cost of different bed types available
  4. Indirect Cost savings for the NHS from reduced time spent searching for bed availability (currently manual process)
  5. Streamlining the whole process makes a more 'digital' experience for all staff which has indirect benefits attributed to a more modern NHS.
Online Discussion Rating
3.75 (4 ratings)
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
Patients would be more likely to be placed in beds nearer to their home.
Current and planned activity: 
Answer Digital are currently working with mHabitat, Leeds Partnership NHS Trust to explore how a Community of Interest could be formed in the north of england. We are interested in working with the WMAHSN too for a community of interest in the WM area.
What is the intellectual property status of your innovation?:
Intellectual Property restrictions have not been applied to this innovation
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Regional Scalability:
As a hosted service, the potential for scalability is tremendous.
Measures:
We will be working with the Community of Interest to establish baseline measurements, especially around the time spent logging bed availability in the current manual process and then the time spent ringing round other NHS and private organisations to find an available bed.
Adoption target:
Small community of interest in a locality with 6 months
Regional adoption within 12-18months
National adoption with ~24 months
Read more
Hide details
Andy Williams 29/02/2016 - 17:16 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Clinical CARPS improves patient care outcomes & staff experience through effective management, distribution & prioritisation of work
#Clear, consistent, flexible task allocation
#Real-time workload understanding
#Data for analysis & improvements
Overview of Innovation:
Clinical CARPS (C-CARPS) is a simple to use clinical task management system. Users have been delighted with the speed of implementation & the ability to fine tune the system to their needs
The system improves patient care outcomes & the experience of clinical staff in a very cost effective manner by saving time, optimising the deployment of staff resources & identifying areas for improvement. 
C-CARPS has been implemented with great success by the Hospital at Night team at The Alfred Hospital, Melbourne with our co-developer partners, InControl Australia. Alfred Health have cited many achievements facilitated or directly enabled by the system:
  • improved performance against patient care targets e.g. 8% increase in emergency patients admitted within 4 hours
  • increased overall productivity
  • improved staff attitude towards the overnight shift
Alfred Health won the “The Premier’s Award for Advancing Healthcare 2013”  & "The Metropolitan Health Workforce Initiative Award 2014" for their achievements, in which C-CARPS was instrumental.
C-CARPS replaces the existing method of task allocation, typically reliant on paging & phone calls between staff to clarify patient needs. In simple terms it is used as follows:
  • Nursing staff issue clinical task requests from ward PC’s or mobile devices
  • Team members carry a mobile device to track, manage & update allocated tasks
  • “Clinical Leads” have the ability to re-allocate work according to demand
  • Handovers are managed quickly & safely through the system
Task requests contain all the information required to immediately prioritise & complete the task. Geographic, nurse & patient identifiers provided by C-CARPS task requests optimise efficient task allocation, improve communication & help prevent errors
The ‘Clinical Lead’ can see all tasks in real time and redistribute them as appropriate. This allows free staff to ease the burden on others, preventing individuals from being overwhelmed & minimising delays. Clinical Leads now redistribute around 14% of the work on a nightly basis.
Data from C-CARPS is used to identify long trends & to understand the type of work carried out by specific staff at night. This has provided supporting evidence in cases of complaints or concerns from staff & enabled the implementation of organisational or procedural change to improve staff utilisation & patient care. In one instance, C-CARPS data was used to reduce the overnight drug chart re-writes average of 42 to 2.5
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
  • Saves nursing and clinical staff time by communicating task information in a clear, complete and standardised way, giving staff more time to focus on the tasks themselves and to progress patient care and professional development
  • Clear visibility of entire workload means that teams can respond dynamically in busy periods by re-allocating work to optimise use of valuable resources in real-time
  • A more responsive and even workload distribution ultimately results in fewer delays and reduced risk of clinical errors due to unmanageable workloads, stress levels or ‘burn-out’
  • Improved handover between shifts, saving time and reducing the likelihood of errors
  • Transparency of the system promotes a team ethic and a shared workload mentality
  • The centralised, time-stamped and easily accessible data will save time reporting on:
    •  Performance, creating new opportunities for performance analysis, promote continuous improvement of working practices and monitor any changes.
    • Resolve any complaints or disputes easily by reviewing real time data evidence.
Additional Information
Please watch the presentation “Data to Transform: Electronic Task Management in the After Hours” by Alfred Health’s Benjamin Warren (Redesigning Care Project Officer at Alfred Health) and Dr Kyle Brooks (Senior ICU Registrar and overnight Clinical Lead at The Alfred), available through the InControl Australia YouTube Channel:

https://youtu.be/NmHE0Jg4DXU

Please view the presentation slides, including graphs, from a presentation delivered by Andrew Stripp, Deputy Chief Executive & Chief Operating Officer of Alfred Health, at the 2014 Emergency Department Management Conference in Melbourne, Australia, which demonstrate the instrumental role Clinical CARPS has played in the success of Alfred Health’s ambitious and award winning “Timely Quality Care” initiative:
http://www.slideshare.net/informaoz/andrew-stripp-alfred-health

InControl Australia have produced a short demonstration video entitled “CARPS Clinical Task Management Overview”, showing the basics of task allocation and distribution between the controller PC software and an Android smart device:
https://youtu.be/3a9yaZ1z8L0

 
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Clinical CARPS is a tool that enables safer, more efficient working practices and improved opportunities for performance analysis, facilitating the implementation of further improvements. This can reduce the costs associated with care delivery and dealing with errors and delays.
  • Saves nursing and clinical staff time
  • Allows staff to progress patient care and professional development
  • Provides clear visibility of entire workload to optimise use of valuable resources in real-time
  • A result of workload distribution  is fewer delays and reduced risk of clinical errors  by managing workloads and stress levels and avoiding ‘burn-out’
  • Reducing the likelihood of errors via Improved handover between shifts and saving time
  • Transparency of the system promotes a team ethic and a shared workload mentality
  • Time-stamped and easily accessible data reporting:
    •  new opportunities for performance analysis to promote continuous improvement of working practices whilst monitoring any changes.
    • Easily resolve any concerns, complaints or disputes by reviewing real time data evidence.
 
ROI
  • The potential exists for very high return on investment, depending on the relative efficiency of the hospital’s existing processes. A user of the original CARPS system cited recovering the original investment every four months! The non-clinical version of CARPS typically recovers initial investment within 18 months. We are awaiting analysis of data on installed versions of Clinical CARPS. We are expecting similar or even better results, due to potential cost savings within a clinical environment.

    Note: Our previous model is used successfully within 15 UK NHS trusts to mange non-clinical tasks
Current and planned activity: 
Currently ‘Clinical CARPS’, Clinical Task Management System is being used in Australia and seeking first adoption within the NHS in the UK. We are looking to NHS organisations within the West Midlands to discuss the possibility of adopting the clinical version on a trial-to-permanent basis.
 
We are seeking collaborations with West Midlands NHS trusts, clinical speciality services or an NHS region to experience our technology, understand the simplicity of installation and to witness the benefits that it can bring to managing the clinical workload, especially out of hours where resources may be limited or stretched and thus not immediately available unless the work flow is adjusted. 

Evaluation/Validation – We are seeking a trial centre to work with to gain additional evidence & validation of the benefits that our software delivers

We look forward to discussing with West Midlands Clinical Management teams how ‘Clinical CARPS’ can transform their task management processes.

.
What is the intellectual property status of your innovation?:
Clinical CARPS is the property of In Control Pty Ltd, co-developer partners of Purcell Radio Systems Ltd. Purcell Radio Systems Ltd have sole rights for the distibution of Clinical CARPS within the UK and Europe.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Regional Scalability:

All of our solutions are highly scalable and an installation of CARPS software will typically lead to a future expansion of the system within that site or further installations at other sites within the region or company, usually by word of mouth promotion. Pricing for individual software licences will come down where larger systems are purchased within a single contract. Depending on the needs of the client we would expect to have a single installation up and running within 2 - 3 months.

Measures:

Quality: We expect Clinical CARPS to improve the quality of communication regarding clinical task allocation, for instance Clinical CARPS task requests can be configured for required minimum information to be mandatory. We would expect this to be measurable by a reduction in the amount of time spent on task allocation (phone calls, conversations, etc) and an increase in productivity in the undertaking of the clinical tasks themselves (delivering patient care). We would expect the enhanced analytical possibilities enabled by CARPS data capture to result in the identification of improved working processes, which should also be taken into account as measures of the system's success.
Safety: We expect patient care outcomes to improve based on the fact that Clinicians and nursing staff have more time available to deliver care as above and can re-allocate work according to demand, priority, availability and suitability. We expect to see measurable improvements against patient safety targets such as improved performance against the four hour admission target from emergencey and a reduction in errors and delays to patient care. As above, any improvements to patient safety made possible through CARPS enhanced data capture should also be counted.
Cost: Return on investment can be measured against increases in productivity on the front line and relating to time saved on performance analysis and the production of reports performed my clinical Management. We would expect complaints to be reduced and costs around the complaints process should also be factored in. A normal CARPS system would be expected to cover the cost of implementation within 18 months and we might cautiously expect even better results within the clinical environment, due to the increased value of the resources involved.
People: Feedback from users and stakeholders should give evidence of an improved attitude towards the way clinical tasks are managed compared with the preceeding system.

Adoption target:

Minimum viability would be the out-of hours clinical team at one hospital. After confirmation of the system's success, we would hope to expand use to 24/7 and to implement the system at other hospitals within the WM region.

Read more
Hide details
Tom Purcell 18/02/2016 - 12:27 Detailed Submission Login or Register to post comments
3.7
3
Votes
-99999
Innovation 'Elevator Pitch':
OsCare Sono allows early assessment of Osteoporosis risk in an out of hospital environment. It is a low cost device, can be used by any healthcare professional, emits no radiation, proven technology & vastly improved patient outcomes and cost savings
Overview of Innovation:
The OsCare Sono™ measures ultrasound wave propagation longitudinally in the radial bone. In comparison to other ultrasound bone sonometers, the OsCare Sono™ has a lower ultrasound frequency, of about 200 kHz. The low frequency ultrasound travels deeper in to the bone tissue providing better correlation with cortical thickness and its patented transducers and algorithms help to eliminate the effect of soft tissue. Oscare Sono also uses the radial bone which is easier to access and more sensitive to osteoporotic changes.

The device compares the measurement result to the available reference population group data and calculates the Z- and T-Score values, indicating if the patient has an increased risk of osteoporosis and future fractures.
OsCare Sono™ measurement results help to recognize those individuals who are at higher risk for osteoporosis and potentially further investigations such as a DEXA.
Osteoporosis is an increasingly prevalent skeletal disease characterized by diminished bone strength and increased risk of fracture which costs the NHS £2.9bn annually.

‘The International Society of Clinical Densitometry (ISCD), the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economical Aspects of Osteoporosis and Osteoarthritis (ESCEO) describe in their position statements that although DXA (dual X-ray absorptiometry) and the femoral neck are the reference technology and site for diagnosing osteoporosis, other techniques such as quantitative ultrasound (QUS) can be used in clinical practice to identify patients at high or low risk of having osteoporosis. The Foundation and Societies stated that QUS is proven to predict osteoporotic fractures similarly to central DXA.’

Oscare Sono is highly portable and can be set up within minutes in an environment suitable for assessing patients.
No ionising radiation is emitted and therefore there is no restriction on location or IMIR regulations.

Early assessment of patients at risk of Osteoporosis in the NICE pathway will identify patients at risk of osteoporosis and allow early intervention.
Oscare will enable large scale assessment of patients at risk of Osteoporosis, facilitate early intervention and improve patient outcomes.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Features:
  • Low-frequency (200 kHz) axial ultrasound velocity correlates well with bone mineral density (BMD) and cortical thickness, giving valuable information on bone strength
  • No ionizing radiation — measurement can be performed in any suitable location and repeated when required
  • Facilitates assessment in any appropriate setting, GP surgery, pharmacy etc.
  • Short assessment time, typically 10 minutes per patient
  • OsCare Sono™ is cost-effective and enables large scale assessment – A reliable and quick procedure
  • No specialised or qualified staff needed, short training cycle, easy to interpret report.
  • Measurement is on the radial bone which is easily accessible so no need for patients to undress
  • Patented soft tissue disturbance effect eliminates artefact producing a clear signal and improved diagnostic confidence
  • Compact in size & highly mobile. No dedicated PC needed, software runs in a standard Windows operating system
Cost savings from:
  • Reduction of referrals for DEXA scanning
  • Potentially significant cost savings in treating reduced numbers of fractures
  • Reduced demand on downstream services as 70% of patients with #NOF or pelvis fail to make a full recovery
  • Reduced emergency admission for osteoporotic fractures
The International Society of Clinical Densitometry (ISCD), the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economical Aspects of Osteoporosis and Osteoarthritis (ESCEO) recognize QUS methods as relatively inexpensive, transportable and proven to predict osteoporotic fractures as well as the central DXA. Compared to DXA, the OsCare Sono™ device is significantly less expensive, portable and, importantly, free of potentially harmful ionizing radiation.

Return on Investment
  • NHS Osteoporotic fracture burden is £2.9 or 3.5 Bn, depending on source
  • Identifying patients who may be at risk or actually have osteoporosis is not being undertaken currently at the rate which is needed. As the population ages, this will become more significant
  • The device is 80% the cost of one A&E admission
  • Early identification reduces decades of patient treatment costs
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Early assessment of patients will facilitate early identification of patients at risk of osteoporosis and enable early intervention. This will lead to reduced incidence of osteoporotic fractures, related mortality and morbidity and associated health costs.
It will dramatically improve patient outcomes by reducing the significant mortality and morbidity associated with osteoporosis which is frequently overlooked as a consequence of being older rather than a modifiable outcome - which it is.
There are currently not enough DEXA scanners in the West Midlands region to cope with demand.
The adoption of this technology within the West Midlands and across the UK. Would not only save some patients the inconvenience of going for a DEXA scan or even repeated scans, when they are not required whilst still providing the patients with confidence and reassurance.
This is not intended as a replacement for DEXA which is still the gold standard in diagnosis of Osteoporosis. This would mean that patients referred for DEXA scanning would have a higher diagnostic yield.
This in turn would reduce the costs of DEXA referrals and investigations for GPs/CCGs to where they are required thereby reducing the waiting times for such investigations and the costs and time associated with reporting negative results on the imaging consultation service and the GP on a subsequent patient visit to collect results.
It is estimated that Oscare Sono will facilitate a reduction of DEXA referrals which cost in the region of £278 per patient. The total number of DEXA scans undertaken in the region and the outcome is not known. But it is clearly not enough as many thousands of patients suffer osteoporotic fractures still and this number will continue to rise as the population ages.
Physiological Measurements Ltd are working closely with the Finnish inventors or this product and have secured a UK distribution and support agreement. The regional and wide scale adoption of this technology would allow the company to grow and take on additional specialist staff to train and support users of this technology as well as having a significant impact on the company and West Midlands Osteoporosis services.
Current and planned activity: 
The device and concept are a disruptive innovation and are not currently in place within the UK healthcare system.
We are about to start a small scale trial with a GP in the Northwest of England and a Pharmacy in the Midlands to gauge acceptance and identify how many people in a cohort are found to be at risk. We are contacting lead commissioners and clinical leads at each of the 44 CCGs that we are currently delivering services too.

Planned / required activity:
  • Procurement / Adoption of our OsCare Sono – First Line Osteoporosis Assessment technology -  We seek to disseminate via the network to clinicians at all levels, the potential impact of this innovation in terms of improved patient outcomes and a reduction on healthcare resource use at all levels.
  • Evaluation / Validation / Clinical Trial  - We would welcome the opportunity to work with an acute NHS trust to evaluate the impact this innovation could have on patient flow and also as a primary prevention tool.
What is the intellectual property status of your innovation?:
Patented Product held by Oscare Medial OY, Finland

Product Certification: CE IIa ref:0537 - - EC-Certificated 93/42/EEC - ISO13485:2003
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jon 08/02/2016 - 17:14 Publish Login or Register to post comments
4.2
5
Votes
-99999
Innovation 'Elevator Pitch':
​LIAISE is a cloud-based platform that harvests information from publicly available and third party sources and auto-combines with your own spreadsheet data to identify accessible efficiencies 
Overview of Innovation:
In an ideal world, cash would be available for investment in new services and models of care.
 
In reality, however, almost all of next year’s fund - £1.8bn of it – will be spent on bailing out NHS providers in deficit, leaving just £339m to fund ‘transformation'
 
With this in mind and alongside the Lord Carter of Coles' report on Adjusted Treatment Cost (ATC) we have been conscious that Trusts need some help in unpicking what this all might mean for them.
 
The Health Service Journal analysis published on January 5th gave you a potential savings figure using reference costs.
 
Several observers have commented that they were expecting something a little more sophisticated. 
 
We’d like offer you a share of the benefits achieved with other NHS Trusts and public sector bodies by use of our LIAISE platform.
 
Others have commented how we have brought into clear view a number of savings opportunities that were hidden - even though they can be identified from a sophisticated analysis of publicly-available data and cross comparison to in house spreadsheet data
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Avoid un-necessary consultancy costs
  • Unlock dead budget
  • Self supported business improvement
  • Accurate management information
  • Reduce spreadsheet dependency / and single points of failure
  • Reduce lost time (FTE days)
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Reduction in bottom line costs without the need for outsourcing or redundancies
More available cash to pay for transformation and future health care system jobs
Current and planned activity: 
We have worked with Bradford District Care Trust, Heart of England NHS Foundation Trust and have proposals in with Sandwell and West Birmingham NHS Trust. Our ROI is between 3,000 and 10,000%. IE for every pound spent we will model £3 - £10k of savings
Demonstrations of capability provided;
  • St Andrews Healthcare – We have just undertaken a high level demonstration  benchmarking suggesting achievable targets of between £4 and 26 million which is representative of 2 – 14% against an income of £189m
  • Bradford District Care trust Estates Department - We have benchmarked the ED against direct comparators and demonstrated £140k to £2m which is representative of 1% and 14%
  • Heart of England NHS FT - We have benchmarked the ED against direct comparators and demonstrated  procurement savings of £910k and operational efficiencies of between £265k and £9m which would is equivalent to a 6400% ROI. Assuming £4.5m / 50% of savings are realised
What is the intellectual property status of your innovation?:
Fully owned by Alphafish associates
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:

We are concentrating our efforts on sales in the UK with an initial focus on the NHS and specifically the 38,000 managers who have an immediate need to find efficiencies totalling £22bn with a government investment of £8bn. We will expand into the entire public sector and then beyond into the $2.7bn global market as defined by Gartner
 
Analysts to Discuss Business Intelligence Trends at Gartner Business Intelligence and Information Management Summit 2013, June 10-11 in Mumbai, India. Worldwide business intelligence (BI), corporate performance management (CPM) and analytics applications/performance management software revenue totalled $13.1 billion in 2012, a 6.8 percent increase from 2011 revenue of $12.3 billion, according to Gartner, Inc.

From the experience we have to date there is considerable opportunity for Cloud CIO in the UK before venturing to Europe and the East Coast of the USA. 
 

Measures:

We believe we can build a cost down business model that helps the NHS to reduce consultancy costs by 30%, saving the NHS a potential £100m million per year.

 

Adoption target:

Market Share – NHS managers only 
User licenses @ £2k (min 10 users)

  • 5% = £3.7m
  • 10% = £7.4m

Upsell 1, auto-combine own systems based on 50% of users @ +1k per pack 

  • 5% = £0.9m
  • 10% = £1.85m

Upsell 2, 30% professional services

  • 5% = £1.1m
  • 10% = £2.2m

Total

  • 5% = £5.7m
  • 10% = £11.9m
Read more
Hide details
Neil Streets 29/01/2016 - 11:44 Detailed Submission Login or Register to post comments
4.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Neurocare’s™ muscle stimulation  therapy is safe, comfortable, non-invasive and clinically proven to accelerate  wound healing and musculoskeletal  rehabilitation which enables major treatment  cost reduction with  significant increases in HRQoL.
Overview of Innovation:
Neurocare™are seeking to promote the adoption in the UK of their muscle stimulation device and its comprehensive treatment protocols .
 
Neuromuscular electronic stimulation therapy is well established in many countries in the world particularly in the U.S.A. and with six FDA indications has a strong clinical trial evidence base in most of its  applications.  The Canadian and American Health Authorities have recommended its use in healing pressure ulcers as did the EPUAP/NPUAP collaboration in work published in 2009.
 
Patient compliance is potentially a challenge particularly where adherence to a treatment programme over a period of time is necessary. Many muscle stimulation devices can be painful  when set at voltages required to achieve a therapeutic level of muscle recruitment.
 
The Neurocare™ device has a unique electronic configuration which features AC output and allows very high voltage for full muscle recruitment at very low amperage for pain free comfortable therapy. Whether treatment occurs in clinic or in the home the objective is to recruit the patient as an enthusiastic active participant in their own programme of therapy.
 
The Neurocare™ device functions by introducing an electrical signal into the motor nerve of the muscle causing a muscle contraction which replicates exercise whilst activating the peripheral arterial and vascular systems which are essential to moving freshly oxygenated blood through the wound site.
 
Each treatment lasts between 30 to 45 minutes and may be administered once or twice daily as necessary at a cost of approximately £2 per treatment.
 
As an option remote web-based management incorporating a “virtual clinic” allows home self-treatment without the presence of healthcare professionals facilitating much more intensive therapy than periodic clinic/outpatient visits allow. This has potential for substantial cost reductions and significant acceleration of healing wounds or musculoskeletal rehabilitation with consequent improvement in HRQoL and timescales reduction.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Clinical trials and evidence / Innovation and adoption
Benefit to NHS:
As an adjunct therapy, NMES devices have been shown in clinical studies to reduce healing timescales compared with existing treatment pathways.  This is true of wound healing and musculoskeletal rehabilitation in general.
 
The Neurocare™  device is  simple,safe, non-invasive and comfortable. It is suitable for use in hospitals, clinics and the home and can be self-administered which permits both logistically and financially very much more intensive therapy than could be achieved with multiple visits to a clinic for outpatient treatment.
 
With the addition of the web-based management system the patient and Healthcare Professional can maintain constant contact for monitoring and management of the patient’s progress thus minimising the frequency of outpatient visits.
 
As an example diabetic ulcers are known to be slow healing. Six months plus  would be typical and many endure well in excess of one year. An adjunct therapy which can reduce  healing timescales by 25%+ and in many cases avoid patient episodes such as  revascularisation and amputation clearly reduces costs and radically improves the outcome for patients.
 
Many of the documents attached evidence the potential improvements accessible with this therapy which is very versatile and will bring more effective resource utilisation, cost reduction and improved patient outcomes across its very broad range of applications.
 
Web-enabled home self treatment accords well with NHS strategic priorities which stress the objective of bringing treatment closer to the patient and highlight the increasing importance of improving the patient experience.
 
Once established as a cost effective way of achieving wound healing the concept of using web-enabled treatment would be extended on a broad front. With NMES an extensive range of medical conditions can be treated remotely. The use of the Internet and the “Virtual Clinic” staffed by multi disciplinary experts allows scarce expert resources to be active over very large patient populations whilst simultaneously permits the patient to remain under the general care of their GP Practice.
Initial Review Rating
3.80 (3 ratings)
Benefit to WM population:
A healthy population is likely to be more productive than an unhealthy one and increasing productivity creates increasing wealth per capita. Healthcare delivered in the most productive way means that for each resource unit consumed more units of healthcare can be delivered.
 
Incremental productivity gains are largely driven by innovation but if maximum value is to be gained  proven innovation must be rapidly adopted and diffused.
 
Today’s aging population is increasingly frail and high quality care is increasingly expensive . Expectations will not be met if innovation driven productivity improvement stalls.
 
In a definitive NHS Document entitled ”Innovation Health and Wealth” published in Dec 2011, Innovation is defined as “An idea service or product new to the NHS or applied in a way that is new to the NHS, which significantly improves the quality of health and care wherever it is applied”. To this end the document recommends inter alia that the NHS should strive  to embrace innovation and become an early adopter, should make full  and early use of digital technologies and increasingly shift focus  toward early diagnosis and prevention,
 
The innovation proposed in this document accords well with these aspirations in that we are proposing the widespread adoption and diffusion of a clinically proven but as yet sparsely adopted medical technology supported by a state of art web-based management system.
 
Healing diabetic ulcers with home self-treatment has been chosen to illustrate the potential of web enabled management of NMES therapy  in this document but the same principles may be applied wherever this form of therapy has proven efficacy.
 
Effective prevention is difficult to prove clinically but several trials have shown that pressure ulcers can be prevented using NMES and the restoration of muscle strength and balance may extend self sufficient independence and thus delay nursing home and/or inpatient costs.
 
The way is open for CCGs to finance adoption trials at relatively low cost and risk pending widespread diffusion.
 
Current and planned activity: 
We are working with
1). Prof. Michael Edmonds at the Diabetic Foot Clinic - Kings College London.
2). Mr. David Russell at the Limb Salvage Clinic - Leeds NHS Trust
3). Prof. Ian Chetter - Vascular Surgeon at Hull NHS Trust

preparing an application for RfPB.

We also recently participated with other NHS hospitals & their Test Beds applications. We are continuing work with the Leeds Academic Health Network.
 
We are currently also working with four further AHSNs; East Midlands, West Midlands, West of England, Yorkshire and Humber.
  • Evaluation / Validation / Clinical Trial - Need to gain additional validation of system within the UK – Thus seeking a trial centre.
    Leading to:
  • Procurement / Adoption - Require addition assistance and validation to support UK sales and marketing to UK treatment centres within Acute and Primary sectors
What is the intellectual property status of your innovation?:
The device IP belongs to Neurocare Europe Limited under license from Neurocare  Inc USA.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Patricia Forrester 22/01/2016 - 15:45 Publish 1 comment
3.6
5
Votes
-99999
Innovation 'Elevator Pitch':
myCOPD is the first step for patients in having their COPD pathway online. 98% of patients had their inhaler technique corrected with no clinical interaction with myCOPD.
Overview of Innovation:
myCOPD is a complete online self-management solution for patients with COPD. Developed under a £1millon NHS contract, myCOPD was selected by Sir Bruce Keogh for the NHS Innovation Accelerator Programme.
https://mycopd.mymhealth.com
https://mypulmonary.rehab
myCOPD is able to deliver the expertise normally provided by the consultant, nurse, physiotherapist, pharmacist and even psychologist at a time and place to suit the patient.
Built by clinicians and tested with patients, myCOPD delivers a simple, functional user interface that can be accessed on any device that connects to the Internet from smartphones and tablets to laptops and desktop computers delivering advanced patient self-management, education, pulmonary rehabilitation and disease management at an individual and population level.
myCOPD brings together patients and clinicians in a single, integrated platform delivering an interface for the clinician managing a population of patients with COPD. The clinician dashboard allows the prompt identification of patients with worsening symptoms. Allowing clinicians to monitor their population more efficiently and allocate resources more appropriately. 
myCOPD is scalable, fully language and region translatable allowing the application to be used in multicultural communities and wider markets in Europe and beyond.

myCOPD has proven to correct 98% of inhaler errors (present in over 90% of patients) with no other clinical intervention.

Patient features
  • An interface where patients can feedback their symptoms and quality of life scores to their health care provider
  • Online self-management plan
  • Patient education
  • Online inhaler diary
  • Oxygen alert card
  • Inhaler technique videos
  • Comprehensive online pulmonary rehabilitation program
Clinician features
  • Community/Exacerbation Review
  • Primary Care Review
  • Secondary Care Review
  • Oxygen Assessment
  • Spirometry
  • Medicine use review
  • Upload any document
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
There is no cure for COPD and good symptom management is essential to stablise disease and prevent recurrent flare-ups or exacerbations. Exacerbations often require intensive treatment and can be severe enough to require hospital admission. COPD is associated with considerable costs, both to the NHS and to society. COPD is the second most common reason for emergency admission to hospital, accounting for one in eight non-elective admissions1. In England in 2012-2013, there were 121,836 admissions for COPD of which the vast majority (95%, n=115,814) were emergency admissions.
From a clinical standpoint, the benefits of systematic symptom documentation, explicit care planning, improved inhaler technique, improved adherence and better access to pulmonary rehabilitation can all be expected to yield improved disease control. The myCOPD system has been evaluated and each individual component has been shown to reduce the likelihood of an acute exacerbation or allow it to be identified early enough to avoid hospital admission. This has clear cut economic benefits.
Prior to going onto myCOPD, over 90% of patients were not able to use their inhalers properly, after 3 months with no clinical interaction the patients were re-evaluated. The result was that 98% of patients were then able to use their inhalers properly with no clinical errors. 95% of patients improved their CAT score. The cost of medicines wastage to the NHS runs well into the millions, add on the fact that patients are not able to take their medications we are wasting money on medications on a large scale.
Now if patients were able to take their inhalers properly and we start to see the drug trial results with exacerbation reduction by around 25%, the savings would be on a large scale. There is an economic evaluation attached which was completed by a third party prior to our SBRI Phase II application for detailed cost savings.
When it comes to Pulmonary Rehabilitation, we are able to provide this at 100th of the cost of current channels.
 
Online Discussion Rating
4.83 (6 ratings)
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
We believe that self-management should begin at the point of diagnosis. We need to put the right tools in the patient’s hands at the start of their pathway, not at the end, not in the middle or somewhere in between, but at the start. Mortality in COPD is high, patients do not want to go to hospital and will often turn to the internet when they need answers about their disease. For most of us, our lives are managed online – banking, shopping, to name a few but not our health, for now. Having a better-educated COPD population, that can access the information they need and more, which has been written by NHS respiratory specialists, will ensure patients understand their disease like never before. Are able to keep track of symptoms and medicines usage. What we will start to see is a better informed patient population, that understands when their CAT scores are getting higher they need to start their rescue pack – that will not only save a nurse/GP appointments but help the patients recover quicker.
Pulmonary rehabilitation (PR) is delivered at a dictated time, day and place – thus resulting in only 5-7% of the eligible COPD population being able to access PR. For the first time the WM population will have the option of opting to do their classes either face to face through the traditional channels, or online or as part of a blended programme where they can access both face to face and digital. Thus delivering real patient choice to how and where they receive their rehab care. 

 
Current and planned activity: 
Back in July, Sir Bruce Keogh announced after a global calling that they had selected 17 proven technologies to be rolled out at scale across the NHS, in line with the vision of the Five Year Forward View. myCOPD was one of them and the only respiratory selection. Over the last 6 months we have been working with many senior figures across the NHS to uncover the barriers and real drivers for change. We have focused our activities with aligned AHSNs and the largest COPD based CCG populations. We want to raise awareness that a digital self-management solution is now available for those with COPD, the aim is to get the solution commissioned across CCGs so all patients are able to access it.
 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
The innovation is easily and readily scalable. All data that feeds into myCOPD sits on servers at Portsmouth NHS Trust on the N3 network. As this is an online solution, scalability is not an obstacle, it has been built on Cassandra databases which means linear scaling is infinite - these are the same platforms Netflix, Google and other use. When a CCG has full access to myCOPD it is easy to create user/patient accounts - with the click of a button.
 
We have not scaled in any other area - we have only been fully ready for market since December 2015.
 
Measures:
The outcomes are reductions in hospitals admissions, re-admissions, increased access to pulmonary rehab, increased completed number of pulmonary rehab attendees, a significant improvement in inhaler/medication adherence, improvement with inhaler technique.
 
Imbedded within the programmes for the patients is the COPD Assessment Test (CAT). Which is a patient-completed instrument that complements existing approaches to assessing COPD impact. It has been designed to provide a simple and reliable measure of health status in COPD and assists patients and their physicians in quantifying the impact of COPD on the patient’s health. 
The CAT has undergone a rigorous, scientific development process and the first validation studies show that it has properties very similar to much more complex health status questionnaires such as the St George’s Respiratory Questionnaire (SGRQ) that are used in research studies. It takes only a fraction of the time to complete, however, making it suitable for routine use. It is and has been used in COPD studies in Europe, USA and Asia. 
 
Year on year admissions into hospital with COPD are increasing, the impact the solution makes on the patient population can be measured through past admissions data Vs. patients on myCOPD and looking at re-admissions data.
 
Adoption target:
Is for 3-5 CCGs in the WM provide access for patients to both myCOPD and myPR within the next 12 months. This will provide access to at least 6,000 patients. It can used within the community, primary care and secondary care teams. There is currently a complete abscence of relaible tools for patients and clinicians in the digital space for COPD.
Read more
Hide details
Ian Thompson 11/01/2016 - 12:28 Sign Posted 12 comments
0
0
Votes

Innovation 'Elevator Pitch':
Software that automatically engages with stakeholders to track performance & risk and identify continuous improvement opportunities in campaigns and/or contracted out services.
Overview of Innovation:
Do you find it difficult to track and measure contract or campaign performance? Compared to well-managed contracts/campaigns, unmanaged or poorly managed contracts/campaigns can lead to costly inefficiencies, poor performance and an increase in risk.
ContractsWise is now offering its innovative, cloud-based contract management tool: ECMS, (available via the Crown Commercial Services G-Cloud Framework Agreement if required). Designed by experienced contract managers, ECMS can increase performance and savings, improve service quality, and mitigate risk, with an automatically backed-up database to prevent loss of data.
Some of ECMS’s features include:
  • A  register to record all contracts/campaigns and associated documents in a secure database
  • A dashboard that can be individually configured for each user, with information on performance and risks
  • Compatibility with any device with a web-connection, including tablets and smartphones, without the need to download additional software
  • Actively and automatically engage with stakeholders.
For those who don’t need all of ECMS’s features, there’s ECAS, an administration system that is scalable to your needs and will help improve control of information and documentation.
ECAS’s Entry Level Plan features include:
  • Searchable database of your information and documents
  • Automated reminders for important dates
  • Secure cloud storage with automated data back-up which frees up physical space
  • Archive old information
  • Online tutorials and help documents.
All of ECAS’s features are included in ECMS.
Understanding contract management and how to improve performance can be difficult, which is why ContractsWise also run an online training course: An Introduction to Contract Management, which combines theory and best practice to give you a comprehensive understanding of the subject.
For more information on the ways that ContractsWise can help please visit www.contractswise.com
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There is an increasing body of evidence that shows that organisations incur significant unplanned costs, don't achieve expected savings or service quality as a result of a lack of effective contract/campaign management.
Research by the International Association of Commercial and Contract Management (IACCM) has quantified the value of these losses at the equivalent of 9.2% of revenue.
All organisations want to achieve the maximum value for every pound spent but in the NHS this is critical. ContractsWise provides low cost tools that will enable the NHS ensure that best value is achieved, risks are identified and mitigated and opportunities for continuous improvement are identified.
A business case template is available to download for free from our website www.contractswise.com and the return on investment will include: avoidance of unplanned costs; never miss a contract termination or renewal negotiation opportunity; realise planned cost savings or revenue improvements; reduce administration time; improve internal and external stakeholder relationships; redice risks; improve compliance; improve reporting.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Users of the NHS in the West Midlands will receive improved services and will be able to contribut eto the continuous improvement of services.
Providers of services will have greater control over their budgeted expenditure or revenue.
Current and planned activity: 
Our software has recently been adopted by Western Sussex NHS Trust.
Following a full review of software available on the market The Chartrered Institute of Procurement and Supply (CIPS) chose our software and has been operating with it since February 2015.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:

Being cloud based with minimal training required,the software can be easily scaled nationally and internationally.

Measures:

The goal is to maximise the performance and minimise the risks associated with the delivery of services by a 3rd party. Maximising performance will ensure that value for money is also maximised and will increase end user satisfaction rates. Minimising risks will reduce the possibility of unplanned costs that have not been budgetted for and will help ensure that any planned savings are actually delivered.
Users of the software will be able to continually measure performance and risk using the tools and dashboard built into the software. The users have full control over what it wants to measure so these can include quality, safety, cost and people.
ContractsWise limited will also measure the satisfaction of our customers through engagement with key stakeholders and work with them to maximise the benefits achieved by using the software in order to generate compelling case studies.

Adoption target:

Any organisation, part of an organisation or project whose measure of success relies upon the delivery of services from one or many 3rd parties.

Read more
Hide details
Noel Green 14/12/2015 - 15:53 Detailed Submission Login or Register to post comments
2.8
4
Votes
-99999

Recent Activities

Thomas Hughes voted on Dementia Dekh Bhaal 1 week 5 days ago
Thomas Hughes voted on Knowing Me! 1 week 5 days ago
Clare Chesworth commented on Revamil Gauze 2 weeks 2 days ago
Clare Chesworth commented on Revamil Gauze 2 weeks 2 days ago
Caroline Maries-Tillott commented on Revamil Balm 2 weeks 3 days ago

Active Campaigns